Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
SGMO > SEC Filings for SGMO > Form 8-K on 25-Mar-2014All Recent SEC Filings

Show all filings for SANGAMO BIOSCIENCES INC

Form 8-K for SANGAMO BIOSCIENCES INC


25-Mar-2014

Entry into a Material Definitive Agreement, Financial Statements and Exhi


Item 1.01 Entry into a Material Definitive Agreement.

On March 20, 2014, Sangamo BioSciences, Inc. (the "Company") entered into an underwriting agreement with J.P. Morgan Securities LLC as the representative of the several underwriters named therein (the "Underwriters"), which provides for the issuance and sale in an underwritten public offering (the "Offering") by the Company and the purchase by the Underwriters of 4,444,444 shares of common stock of the Company (the "Common Stock"). The shares in the Offering were sold at a public offering price of $22.50 per share. The Company also granted the Underwriters an option to purchase up to 666,666 additional shares of Common Stock at the public offering price. The Company estimates that the net proceeds from the offering will be approximately $93.8 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company, and assuming no exercise of the option by the Underwriters to purchase additional shares.

The Offering was made pursuant to the Company's effective registration statement on Form S-3ASR (Registration No. 333-194126) and the prospectus dated February 25, 2014 included in such registration statement, as supplemented by a preliminary prospectus supplement dated March 19, 2014 and a final prospectus supplement dated March 20, 2014.

The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, which is filed as Exhibit 1.1 hereto and is incorporated herein by reference. A copy of the opinion of Morgan, Lewis & Bockius LLP relating to the legality of the issuance and sale of the shares is attached as Exhibit 5.1 hereto.

On March 20, 2014, the Company issued a press release announcing the pricing of the Offering. A copy of this press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are attached herewith:

           Exhibit   Description

            1.1      Underwriting Agreement, dated as of March 20, 2014

            5.1      Opinion of Morgan, Lewis & Bockius LLP

           99.1      Press release, dated as of March 20, 2014


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SANGAMO BIOSCIENCES, INC.

By: /s/ Edward O. Lanphier II
Name: Edward O. Lanphier
Title: President, Chief Executive Officer

Dated: March 24, 2014

  Add SGMO to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for SGMO - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.